{
    "success": true,
    "data": {
        "ucits": true,
        "type": "ETF",
        "replication_method": "physical",
        "derivatives": false,
        "swaps": false,
        "inverse": false,
        "leverage": false,
        "complex_factors": [],
        "classification": "non-complex",
        "supporting_data": "The ETF tracks the MSCI ACWI IMI Genomic Innovation Select Index using physical replication. The index methodology is described as publicly available and based on market capitalization and a relevance score, with exclusions based on ESG screening. The fund does not mention the use of derivatives for replication or other purposes, and it is a UCITS ETF, which carries a presumption of non-complexity. The risk profile is category 6, indicating high volatility, but this is market risk and not indicative of structural complexity. Securities lending is mentioned, but as a secondary feature to offset costs, and typically does not render a UCITS ETF complex if managed within rules and with collateral. No other complex features such as leverage, embedded derivatives, or capital protection structures are indicated. The document confirms that UCITS ETFs are generally considered non-complex regardless of their underlying assets (CESR/09-295, page 20, para 70, 80 and Annex I)."
    }
}